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Background
In order to improve the molecular response rate and prevent resistance to treatment, combina-
tion therapy with different dosages of imatinib and cytarabine was studied in newly diagnosed
patients with chronic myeloid leukemia in the HOVON-51 study.
Design and Methods
Having reported feasibility previously, we hereby report the efficacy of escalated imatinib (200
mg, 400 mg, 600 mg or 800 mg) in combination with two cycles of intravenous cytarabine (200
mg/m2 or 1000 mg/m2 days 1 to 7) in 162 patients with chronic myeloid leukemia.
Results
With a median follow-up of 55 months, the 5-year cumulative incidences of complete cytoge-
netic response, major molecular response, and complete molecular response were 89%, 71%,
and 53%, respectively. A higher Sokal risk score was inversely associated with complete cyto-
genetic response (hazard ratio of 0.63; 95% confidence interval, 0.50-0.79, P<0.001). A higher
dose of imatinib and a higher dose of cytarabine were associated with increased complete
molecular response with hazard ratios of 1.60 (95% confidence interval, 0.96-2.68, P=0.07) and
1.66 (95% confidence interval, 1.02-2.72, P=0.04), respectively. Progression-free survival and
overall survival rates at 5 years were 92% and 96%, respectively. Achieving a major molecular
response at 1 year was associated with complete absence of progression and a probability of
achieving a complete molecular response of 89%. 
Conclusions
The addition of intravenous cytarabine to imatinib as upfront therapy for patients with chron-
ic myeloid leukemia is associated with a high rate of complete molecular responses
(Clinicaltrials.Gov Identifier: NCT00028847). 
Key words: imatinib, cytarabine, escalated therapy, combination therapy, chronic myeloid
leukemia.
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Introduction
The introduction of imatinib, a specific kinase inhibitor of
the BCR-ABL protein, has dramatically changed prospects
for patients with chronic myeloid leukemia (CML).1 Most
patients with newly diagnosed chronic phase CML nowa-
days achieve a complete cytogenetic response, which subse-
quently predicts for relatively long survival.2 Moreover,
patients achieving a major molecular response do even bet-
ter, as not a single patient who attained such a response at
18 months had progressed at 5 years.2,3 The recently pre-
sented 7-year follow-up data of the International
Randomized Study of Interferon and STI571 (IRIS) con-
firmed durability of cytogenetic responses and a low rate of
progression.4 However, the estimated 5-year event-free sur-
vival was 83%, and an estimated another 16% of patients
discontinued imatinib for various reasons within the first 5
years.2 Comparable results were observed in a recent large
single center study,5 indicating that although the majority of
patients enter a stable cytogenetic remission, more than one
third of patients may still be in need of alternative therapy. 
Patients needing second-line therapy include patients
who do not tolerate imatinib and patients acquiring resist-
ance. Primary or acquired resistance against imatinib is cur-
rently defined at hematologic, cytogenetic, and also molec-
ular levels.6 It may be caused by different mechanisms,
including point mutations in the BCR-ABL kinase domain,
overexpression of BCR-ABL, additional chromosomal
abnormalities in the Philadelphia (Ph)-positive clone, and a
relative insensitivity of quiescent leukemic stem cells to
imatinib.7-10 Prevention of resistance and improving the
cytogenetic and molecular response rates may be achieved
by different approaches, including dose escalation of ima-
tinib, second-generation tyrosine kinase inhibitors, or com-
bination therapy.11-15 Several combinations have been
explored in vitro and also in early clinical studies.12,16-19
Among the combinations of imatinib and cytostatic drugs,
the combination of cytarabine and imatinib was found to
result in a synergistic effect, especially at higher concentra-
tions of either drug.18,19 Based on these findings, the
HOVON cooperative study group set out to explore the
clinical feasibility and efficacy of the imatinib plus cytara-
bine combination, applying a step-wise dose-increase of
either drug. Recently, feasibility results of that combination
were reported.12 Here, the efficacy of the combination of
imatinib and intravenous cytarabine is reported with
emphasis on the rate and duration of molecular responses as
well as their major determinants.
Design and Methods
The HOVON-51 was a multicenter study designed to investigate
the feasibility and efficacy of escalated imatinib in combination with
intravenous cytarabine in patients with early chronic phase CML.
Inclusion criteria included: age between 18 and 65 years, presence of
the Ph chromosome or BCR-ABL rearrangement, adequate organ func-
tion, registration within 6 months of diagnosis, and no previous treat-
ment except for hydroxyurea. The ethics committees of all participat-
ing centers approved the study and informed consent was obtained
from all patients in accordance with the Declaration of Helsinki.
Patients were recruited from August 2001 to November 2005.
Study design and treatment
The design of the study has been described recently.12 In brief,
patients were assigned to one of seven predefined, successive dose lev-
els. Dose levels were open for inclusion only when the preceding dose
level had met the criteria of acceptable toxicity and safety. First, a pre-
phase of imatinib (400 mg) monotherapy was given to all patients for
2 to 3 weeks. This was followed by combination therapy of two
cycles of intravenous cytarabine (200 mg/m2 or 1000 mg/m2 days 1 to
7) with imatinib (200 mg, 400 mg, 600 mg or 800 mg once daily).
Imatinib (400 mg, 600 mg or 800 mg) maintenance therapy was con-
tinued after the second cycle until disease progression, intolerance of
treatment, or eligibility for allogeneic stem cell transplantation (SCT),
whichever occurred first. Dose adjustments during imatinib mainte-
nance therapy were made in the case of non-hematologic toxicity of
Common Toxicity Criteria (CTC) grade 2 or higher as reported
before,12 and as described in detail at www.hovon.nl.
Definition of end-points
The definition of molecular response was adapted in order to be
compatible with the international scale.20,21 A laboratory-specific con-
version factor to the international scale has been acquired via EUTOS
for CML, which promotes quality controlled molecular monitoring
using standardized real-time quantitative polymerase chain reaction
(RQ-PCR) technologies and establishment of an international defini-
tion of major molecular response (http://www.eutos.org/). A complete
molecular response was defined as no residual BCR-ABL transcripts by
RQ-PCR (in duplicate), corresponding to a greater than 4.5 log-reduc-
tion of BCR-ABL copies. Only BCR-ABL values resulting from assaying
with a level of sensitivity of at least 0.01% in duplicate were consid-
ered appropriate. If cytogenetic results were not available during fol-
low-up, RQ-PCR measurement of BCR-ABL was used as a surrogate
for complete cytogenetic response, with BCR-ABL values below 1%
being considered as indicating a complete cytogenetic response.13,22
Molecular response was centrally assessed at the Erasmus University
Medical Center in Rotterdam using RQ-PCR on peripheral blood
and/or bone marrow. Molecular analysis was done at baseline, after
cycles 1 and 2, at 6 months, and at least every 3 to 6 months thereafter.
All patients who failed to achieve a major molecular response at 1 year
were evaluated for point mutations in the ABL kinase domain, and the
investigation was repeated during follow-up as long as patients failed
to achieve a major molecular response. Patients who lost their initial
response or progressed during follow-up were also evaluated for muta-
tions. BCR-ABL mutation analyses were performed as previously
described.23
Cumulative incidences of response are expressed as the time from
registration to complete hematologic response, major cytogenetic
response, complete cytogenetic response, major molecular response,
and complete molecular response. Loss of complete hematologic
response was defined as a white blood cell count (WBC) greater than
20¥109/L or progression to advanced phase CML; loss of major cyto-
genetic response as an increase of Ph-positive metaphases by at least
30% points to 35% or more Ph-positive metaphases; loss of complete
cytogenetic response by the detection of one or more Ph-positive
metaphases, loss of major molecular response as a 0.5 log increase of
BCR-ABL to a BCR-ABL level greater than 0.1%; and loss of complete
molecular response as renewed detection of BCR-ABL transcript levels.
In the case of loss of hematologic, cytogenetic or molecular responses,
confirmation by a subsequent evaluation at least 1 month later was
required. Progression was defined as the development of accelerated
phase or blast crisis CML, whichever came first. Failure of imatinib
treatment was defined as progression (to advanced phase CML), loss
of complete hematologic response, loss of major cytogenetic response,
or an increasing WBC (defined as doubling of the WBC to greater than
20¥109/L on two occasions at least 1 month apart in a patient who had
never attained a complete hematologic response despite receiving
maximally tolerated doses of therapy). 
Progression-free survival was defined as the time from registration
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until progression or death, whichever came first. Failure-free survival
was defined as the time from registration until failure on imatinib
treatment or death, whichever came first. Of note, primary hemato-
logic resistance is not included in the definition of failure-free survival
due to cytopenias associated with combination treatment, which pre-
cludes an early evaluation of hematologic response. Event-free survival
was defined as the time from registration until failure on imatinib
treatment, discontinuation of imatinib treatment, going off protocol
treatment for any reason, or death, whichever occurred first. Overall
survival was calculated as the time from registration until death of any
cause. Patients still alive at the date of last contact were then censored.
Statistical methods 
The cumulative incidences of complete hematologic response,
major cytogenetic response, complete cytogenetic response, major
molecular response and complete molecular response were calculated
using competing risk analysis. Competing risks were disease progres-
sion, discontinuation of treatment before achieving response, or death
without previous response. As an allogeneic SCT was allowed as off
protocol treatment if no cytogenetic response was acquired within 12
months or according to the physician’s preference, patients who
underwent this treatment were censored at the date of the transplant.
Progression-free, event-free, failure-free and overall survival rates were
estimated by the Kaplan-Meier method, and 95% confidence intervals
(CI) were determined. Patients who underwent allogeneic SCT were
censored at the date of transplantation. Time to response and survival
end-points were illustrated by Kaplan-Meier curves until 5 years.24 In
our trial, patients had been assigned to receive standard- or intermedi-
ate-dose cytarabine, as well as low/standard-dose (200 and 400 mg) or
high-dose (600 mg and 800 mg) imatinib. Univariate and multivariate
Cox regression analyses,25 without and with interaction terms, were
performed to evaluate the effect of higher dose levels and the impact
of the Sokal risk score and Euro score on clinical outcome. Hazard
ratios (HR) with 95% CI were determined. All reported P values are
two-sided, and a significance level of α=0.05 was used.
Results
The patients’ characteristics are presented in Table 1.
The median age at diagnosis was 47 years (range, 19-65
years); patients were fairly evenly distributed among the
three Sokal risk categories. One hundred and sixty-two
patients received a first cycle of combination therapy and
140 patients (86%) also received a second cycle of combi-
nation therapy. One hundred and fifty-seven patients
(97%) started with imatinib maintenance therapy. The
current analysis is based on data collected up to December
18, 2008, resulting in a median follow-up of 55 months
(range, 10-84 months). Currently, 112 patients (69%) are
still on protocol treatment, and 50 patients went off pro-
tocol treatment for various reasons including progression
to accelerated phase or blast crisis in 7 patients, loss of
hematologic or cytogenetic response in 7 patients, no
complete hematologic response at 6 months in 2 patients,
toxicity in 12 patients, proceeding to allogeneic SCT in 18
patients and other reasons in 4 patients. Second-line ther-
apy included allogeneic SCT from either a related or a
matched unrelated donor in 18 patients, nilotinib or dasa-
tinib in 14 patients, chemotherapy in 7 patients, and other
treatment modalities in 7 patients.
Hematologic, cytogenetic, and molecular responses
The patients’ responses are presented in Table 2, and
Figures 1A-C and 2A-B. One hundred and fifty-four
patients achieved a complete hematologic response, 146
patients a major cytogenetic response, and 135 patients a
complete cytogenetic response, based on cytogenetic eval-
uation in 130 patients and quantitative PCR in 5 patients.
The median time to a complete cytogenetic response was
W. Deenik et al.
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Table 1. Baseline characteristics of all patients.
Characteristic All patients
(N=162)
Age at diagnosis, years
median 47
range 19-65
Sex, n. (%)
male 95 (59%)
female 67 (41%)
Sokal risk group, n. (%)
low (< 0.8) 59 (36%)
intermediate (0.8-1.2) 50 (31%)
high (> 1.20) 43 (27%)
unknown 10 (6%)
Euro score, n. (%)
low (≤ 780) 70 (43%)
intermediate (> 780-1480) 57 (35%)
high (> 1480) 23 (14%)
unknown 12 (7%)
Dose of imatinib, n. (%)
low/standard-dose (200 mg and 400 mg) 49 (30%)
high-dose (600 mg and 800 mg) 113 (70%)
Dose of cytarabine, n. (%)
standard-dose (200 mg/m2) 107 (66%)
intermediate-dose (1000 mg/m2) 55 (34%)
Percentages may not sum up to 100% due to rounding.
Table 2. Patients’ responses (N=162).
Type of Response N.
Complete hematologic response
No 8
Progression to accelerated phase or blast crisis 2
Yes 154
Loss of complete hematologic response 9
Progression to accelerated phase or blast crisis 7
Complete cytogenetic response
No 27
Yes 135
Loss of complete cytogenetic response 17
Loss of complete hematologic response 5
Progression to accelerated phase or blast crisis 4
Major molecular response
No 55
Yes 107
Loss of major molecular response 6
Loss of complete cytogenetic response 1
Loss of complete hematologic response 1
Progression to accelerated phase or blast crisis -
Complete molecular response
No 84
Yes 78
Loss of complete molecular response 10
Loss of major molecular response 2
Loss of complete cytogenetic response -
Loss of complete hematologic response -
Progression to accelerated phase or blast crisis -
approximately 4.5 months. In total, 107 patients achieved
a major molecular response, and 78 patients developed a
complete molecular response on protocol treatment. In
addition, we performed nested PCR in 51 of the 78
patients negative by real-time PCR, corresponding to a
greater than 4.5-log reduction of BCR-ABL copies. All but
nine of these patients were also negative by nested PCR.
The median time to major molecular response was 11
months and the median time to complete molecular
response was approximately 22 months. With a median
follow-up of 55 months, 9 patients lost their complete
hematologic response, 16 patients lost their previously
established major cytogenetic response and 17 patients
lost their complete cytogenetic response. Of all 107
patients with a major molecular response, 6 patients lost
that response, and loss of complete molecular response
was observed in 10 patients (Table 2). At 5 years, the
cumulative incidences of a complete cytogenetic response,
major molecular response, and complete molecular
response were, respectively, 89%, 71%, and 53% (Figure
1A-C). Of note, 89% of the patients who achieved a major
molecular response at 1 year subsequently developed a
complete molecular response. Furthermore, none of the
107 patients with a major molecular response subsequent-
ly progressed to advanced phase CML, while 4 out of 135
patients with a complete cytogenetic response and 5 out
of 27 patients who failed to achieve a complete cytogenet-
ic response progressed to advanced phase CML. Among
the 103 patients with a complete cytogenetic response at
1 year, 91 (88%) subsequently obtained a major molecular
response and 71 patients (69%) ultimately developed a
complete molecular response. In contrast, among 41
patients continuing protocol treatment, but who failed to
achieve a complete cytogenetic response at 1 year, 27
patients (66%) subsequently developed a complete cyto-
genetic response at later time points (Figure 1A), 15
patients (37%) attained a major molecular response, and
only 6 patients (15%) ultimately developed a complete
molecular response. 
There were significant differences in the rates of major
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Figure 1. Cumulative incidences of (A) complete cytogenetic
response, (B) major molecular response, and (C) complete molecu-
lar response.
Figure 2. Cumulative incidences of (A) complete molecular response
by dose of imatinib (HR = 1.60; 95% CI, 0.96-2.68, P=0.07) and (B)
complete molecular response by dose of cytarabine (HR=1.66; 95%
CI, 1.02-2.72, P=0.04)
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and complete cytogenetic responses among patients
according to Sokal risk and Euro scores in univariate
analysis. A higher Sokal risk score remained adversely
associated with major and complete cytogenetic respons-
es (HR=0.63; 95% CI, 0.50-0.79, P<0.001) (Table 3) in mul-
tivariate analysis. At 1 year the cumulative incidences of a
complete cytogenetic response was 76% in patients with
a low Sokal score, 74% in patients with an intermediate
Sokal score, and 40% in patients with a high Sokal score.
However, at 5 years these differences in response rates
were less pronounced, being 89%, 93%, and 81%, in low,
intermediate, and high-risk patients, respectively. The lat-
ter higher response rate in high-risk patients at 5 years
appeared primarily due to a slower developing response
rate. A higher Sokal score was also inversely associated
with major molecular response (HR = 0.74; 95% CI, 0.58-
0.96, P=0.02) (Table 3), but not with complete molecular
response. In contrast, the dose of imatinib and the dose of
cytarabine were not associated with cytogenetic response,
but a higher dose of imatinib appeared to be associated
with a better major and complete molecular response rate
(HR = 1.60; 95% CI, 0.96-2.68, P=0.07) (Table 3, Figure
2A). Independently, also the higher dose of cytarabine was
associated with a better complete molecular response rate.
Sixty percent of patients receiving the higher dose of
cytarabine developed a complete molecular response at 5
years as compared to 50% of the patients receiving a stan-
dard-dose of cytarabine (HR = 1.66; 95% CI, 1.02-2.72,
P=0.04) (Table 3, Figure 2B).
Progression-free, overall, failure-free, and event-free
survival
After a median follow-up of 55 months, nine patients
had developed advanced phase CML and three patients
had died resulting in a 5-year progression-free survival rate
of 92% (95% CI, 85%-95%) (Figure 3A). The estimated
annual rate of progression was 5.0% in the first year, 0.7%
in the second year, 0.8% in the third year, 2.2% in the
fourth year, and 0% in the fifth year. Due to the limited
number of events, prognostic factors for progression-free
survival were not evaluated. In total, six patients died,
resulting in an overall survival rate at 5 years of 96% (95%
CI, 92%-98%). The causes of death of these six patients
were blast crisis CML in three patients, excessive toxicity
in two patients and an unrelated cause in one patient.
Recipients of an allogeneic stem cell graft were censored at
the time of transplantation for the latter analysis in con-
cordance with earlier reports and to facilitate compari-
son.2,5 Twenty-seven patients ultimately underwent allo-
geneic SCT as second- or third-line therapy, predominant-
ly because of primary (8 patients) or secondary resistance
(9 patients). Other reasons for performing allogeneic SCT
included intolerance of imatinib (3 patients) and physi-
cians’ preference (7 patients). Twelve out of these 27
patients died due to either non-relapse mortality (n=11) or
progressive disease (n=1). Survival without censoring the
allogeneic SCT recipients at the time of transplantation
was estimated to be 88% at 5 years.
Imatinib treatment failed in 20 patients, of whom 7 pro-
gressed to the accelerated phase or blast crisis as the first
event of treatment failure, 2 patients had an increasing
WBC count, 2 patients lost their complete hematologic
response, and 9 patients lost a major cytogenetic response.
Another three patients died without prior failure on ima-
tinib treatment. The estimated 5-year failure-free survival
rate was 86% (95% CI, 79-91%) (Figure 3A). Neither the
dose of cytarabine or imatinib, nor Sokal risk and Euro
scores were associated with failure-free survival. However,
time-dependent analysis showed that early cytogenetic
and molecular responses had a favorable impact on failure-
W. Deenik et al.
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Table 3. Results of the multivariate analysis.
Parameter Major cytogenetic Complete cytogenetic Major molecular Complete molecular
response response response response
HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value
Dose of cytarabine 1.08 (0.75-1.57) 0.66 1.02 (0.69-1.51) 0.91 1.16 (0.75-1.78) 0.50 1.66 (1.02-2.72) 0.04
Dose of imatinib 1.07 (0.74-1.55) 0.73 1.38 (0.93-2.04) 0.11 1.67 (1.06-2.61) 0.03 1.60 (0.96-2.68) 0.07
Sokal risk score 0.56 (0.45-0.70) < 0.001 0.63 (0.50-0.79) <0.001 0.74 (0.58-0.96) 0.02 0.90 (0.67-1.22) 0.51
Figure 3. (A) Event-free survival (EFS), failure-free survival (FFS), pro-
gression-free survival (PFS), and overall survival (OS). (B) Landmark
analysis of failure-free survival by major molecular response (MMR)
at 1 year.
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free survival. A landmark analysis of the 103 patients who
had achieved a complete cytogenetic response at 1 year
revealed a superior estimated 5-year failure-free survival of
97% as compared to 77% in 41 patients without a com-
plete cytogenetic response at 1 year (P<0.001) (data not
shown). Moreover, the 5-year failure-free survival rate of 61
patients who rapidly achieved a major molecular response
by 12 months was higher than that of the 83 patients who
had failed to attain a such a response by 1 year (100% ver-
sus 86%; P=0.002) (Figure 3B). 
Event-free survival was also assessed. Overall, 50 events
were noted, resulting in a 5-year event-free survival rate of
69% (95% CI, 61%-76%) (Figure 3A). Higher Sokal risk
and Euro scores were associated with worse event-free
survival in univariate analysis. A higher Sokal risk score
remained adversely associated with event-free survival
(HR = 1.55; 95% CI, 1.08-2.22, P=0.02), when adjusted for
dose of cytarabine and imatinib.
Point mutations in the BCR-ABL kinase domain
Patients failing to achieve a major molecular response
at 1 year, and at subsequent evaluation time points there-
after were evaluated for point mutations within the
BCR-ABL kinase domain. In addition, patients with pri-
mary or secondary hematologic or cytogenetic resistance
and all patients who, at any time, progressed to
advanced phase CML were evaluated for mutations. In
total, 153 samples were evaluated for point mutations in
the kinase domain, showing a cumulative incidence of
mutations of 10% at 5 years. In total, 14 different muta-
tions were detected in 15 patients, including 2 patients
with a T315I mutation. Nine of these 15 patients with a
mutation subsequently lost their response, and 3 patients
progressed to advanced phase CML. 
Tolerance of protocol treatment
Adverse events and side effects during the phase of
combination therapy have already been reported in
detail.12 During maintenance, the most frequent adverse
events of CTC grade 2 or more included constitutional
symptoms (34%) and gastrointestinal complaints (33%);
toxicity of CTC grade 3 or 4 occurred infrequently. Both
the incidence and severity of these side effects were
essentially similar to the those of the side effects that can
be observed in patients receiving monotherapy with
imatinib as reported before.2 Combination therapy and
maintenance were well tolerated as illustrated by the fact
that only 9% of patients discontinued treatment because
of side effects (n=15), which represent all discontinua-
tions including the toxic deaths, an event-free survival of
69%, and a total number of 112 patients still continuing
protocol treatment.
Discussion
Imatinib treatment is associated with high rates of com-
plete cytogenetic and major molecular responses in
patients with first chronic phase CML, although complete
molecular responses occur significantly less frequently and
the majority of patients continue to harbor minimal resid-
ual disease, necessitating prolonged treatment with ima-
tinib.2,3,5 With the ultimate aim of improving the complete
molecular response rate, the HOVON study group set out
to explore combination therapy of escalated doses of ima-
tinib and cytarabine. With a median follow-up of 55
months, the long-term efficacy of this combination thera-
py is presented here. The most important findings of our
study include a relatively high complete molecular
response rate, a low incidence of primary cytogenetic and
molecular resistance, and a relatively high number of
patients still continuing protocol treatment, while main-
taining their remission.
The cumulative incidence of a complete molecular
response was 53% at 5 years. A higher dose of imatinib
monotherapy may already be associated with faster and
better responses, although different results were observed
in distinct risk-categories of patients.11,26-29 In addition, an
association has been observed between plasma trough
levels and outcome.30,31 A modest dose-dependent effect of
imatinib was also apparent in our study (Table 2, Figure
3A). Furthermore, the earlier observed in vitro synergistic
or additive effect of cytarabine18,19 seems to have been mir-
rored here clinically. An additive effect of cytarabine is fur-
ther supported by the significant dose-dependent effect of
cytarabine observed in our study. Moreover, up to the lat-
est follow-up, none of the patients receiving the higher
dose of cytarabine has developed progressive disease. A
high complete molecular response rate of approximately
50% was reported earlier by Branford et al.32 These results
cannot be compared directly with those from the present
study, as we estimated cumulative incidences with com-
peting risk-analysis. However, the median time to com-
plete molecular response differed markedly, being 18
months in the present study and approximately 4 years in
the Australian study.32 Recently, Cortes et al. reported
results obtained with 800 mg imatinib in newly diagnosed
patients.33 Approximately 50% of patients evaluable at 18
months after the start of treatment had obtained a com-
plete molecular response, which comes close to what was
observed in the present study, but these favorable results
were obtained in a relatively good-risk group in that 70%
of the patients had a low-risk Sokal score. The issue of an
additive effect of cytarabine does, therefore, remain open,
but may be settled by a prospective randomized trial that
is currently underway. Two other cooperative groups
explored the combination of cytarabine and imatinib. A
French cooperative group demonstrated the feasibility of
imatinib and low-dose cytarabine,16 but their long-term
results are not yet available. An Australian cooperative
group developed a protocol including addition of cytara-
bine for patients failing to obtain a sufficient response 3
months after dose escalation of imatinib. However, only a
minority of patients actually received the combination,
which precludes any definite conclusion as regards the
additive value of cytarabine in their study.13
By inducing a high complete molecular response rate,
combination therapy may prevent primary resistance at
the various levels, and it may also prevent secondary
resistance in patients relapsing from an earlier established
response. Primary cytogenetic resistance, defined as fail-
ure to achieve a complete cytogenetic response at 18
months, was observed in 36 patients (22%) in our study.
Nineteen out of these 36 patients (53%) who failed to
achieve a complete cytogenetic response by 18 months
had a high-risk Sokal score. While a 22% failure rate may
be somewhat lower than that which can be observed fol-
lowing imatinib only (approximately 30% in the
Hammersmith study5), primary cytogenetic resistance is
still of concern and combination therapy only partially
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prevented cytogenetic resistance. It indicates that a subset
of high-risk patients is still in need of a more efficient ther-
apeutic approach. Furthermore, additional parameters
apart from those incorporated in the Sokal and Euro scores
may be needed to more accurately identify the patients at
highest risk of primary cytogenetic resistance. New diag-
nostic techniques such as gene expression profiling and
single nucleotide polymorphisms may possibly add to the
well-established risk scores.34,35 Secondary resistance per-
centages were rather low and progression-free survival
estimated at 92% at 5 years. As outlined by de Lavallade
et al., another important outcome estimate is the 5-year
probability of achieving and maintaining a major cytoge-
netic response, while continuing imatinib. It was 63% for
patients with early chronic phase CML receiving a stan-
dard-dose of imatinib in the Hammersmith series of
patients.5 For comparison, 69% of the patients in the pres-
ent study maintained at least an earlier established major
cytogenetic response and were still on imatinib according
to protocol. Apart from an encouraging efficacy of combi-
nation therapy, this high percentage of patients continuing
protocol treatment also illustrates that combination thera-
py was rather well tolerated. 
Our results, as well as those by several others, clearly
suggest that patients with a more pronounced response,
such as a major molecular response, benefit in terms of a
lower risk of disease progression and prolonged progres-
sion-free survival.2,3,36,37 Therefore, aiming for a major
molecular response has been advocated as an important
treatment goal by several investigators.3,35 Is a further
improvement up to the level of a complete molecular
response of additional benefit? Recent preliminary reports
have suggested that a subset of patients in continued com-
plete molecular response may potentially be cured, as was
suggested by absence of molecular relapse following cessa-
tion of imatinib maintenance initially described by
Rousselot et al.38 A more recent follow-up and inclusion of
a total of 50 patients essentially showed the same picture
with approximately 50% of patients maintaining PCR-neg-
ativity after cessation of imatinib.39 A similar observation
was made in Australia, with a relatively high failure-free
survival rate, but longer follow-up may be needed to deter-
mine definitely to what extent patients may be cured.40
In conclusion, following earlier in vitro findings,18,19 our
clinical results may mirror the contributing effect of
cytarabine to that of imatinib in patients with first chron-
ic phase CML. The additive value of cytarabine in first
chronic phase CML seems to be better eradication of
residual disease, as reflected by a relatively high rate of
complete molecular responses. While cytogenetic resist-
ance may partially be prevented, a subset of high-risk
patients still represents a category of patients for whom
better therapeutic approaches are needed. The ultimate
advantage of an increased complete molecular response
rate should be assessed in future studies, including well-
monitored trials evaluating the cessation of imatinib in
patients with a long-lasting complete molecular response.
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